Dong-E-E-Jiao (000423) Fundamentals 2026 — P/E 18.6x, Revenue Analysis | SniperIQ
Dong-E-E-Jiao (000423) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥32.9B, trading at ¥51.44 on the SHZ. This SniperIQ fundamentals page covers Dong-E-E-Jiao's valuation (P/E 18.6x, P/B 3.1x), profitability (net margin 26.0%), revenue (¥6.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dong-E-E-Jiao's market cap?
Dong-E-E-Jiao (000423) has a market capitalization of approximately ¥32.9B, trading at ¥51.44 on the SHZ. Market cap moves with the live share price.
What is Dong-E-E-Jiao's P/E ratio?
Dong-E-E-Jiao's trailing twelve-month P/E ratio is 18.6x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dong-E-E-Jiao?
Dong-E-E-Jiao runs a net profit margin of 26.0%, a gross margin of 73.5%, and an operating margin of 29.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dong-E-E-Jiao generate?
Dong-E-E-Jiao reported revenue of ¥6.6B for fiscal year 2025, with net income of ¥1.7B and earnings per share (EPS) of 2.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dong-E-E-Jiao pay a dividend?
Dong-E-E-Jiao offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dong-E-E-Jiao financially healthy?
Dong-E-E-Jiao carries a debt-to-equity ratio of 0.01x and a current ratio of 4.20x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dong-E-E-Jiao a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dong-E-E-Jiao (000423) the key facts are: market cap ¥32.9B, P/E 18.6x, revenue ¥6.6B, 52-week range 42.88-58.36. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dong-E-E-Jiao's full fundamentals live
Get Dong-E-E-Jiao's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.